Baseline demographic and clinical characteristics according to the relapse subgroup
| . | Early relapse (<24 mos) . | Late relapse (≥24 mos) . | ||
|---|---|---|---|---|
| DARA (n = 125) . | Control (n = 115) . | DARA (n = 146) . | Control (n = 144) . | |
| Age, y | ||||
| Median (range) | 65 (30-89) | 65 (40-85) | 64 (34-84) | 64 (42-85) |
| ≥75 y, n (%) | 17 (13.6) | 17 (14.8) | 8 (5.5) | 16 (11.1) |
| ISS staging, n (%)∗ | ||||
| I | 62 (49.6) | 51 (44.3) | 73 (50.0) | 81 (56.3) |
| II | 45 (36.0) | 43 (37.4) | 45 (30.8) | 42 (29.2) |
| III | 18 (14.4) | 21 (18.3) | 28 (19.2) | 21 (14.6) |
| Cytogenetic risk, n (%)† | (n = 93) | (n = 93) | (n = 116) | (n = 96) |
| Standard | 72 (77.4) | 72 (77.4) | 94 (81.0) | 85 (88.5) |
| High | 21 (22.6) | 21 (22.6) | 22 (19.0) | 11 (11.5) |
| . | Early relapse (<24 mos) . | Late relapse (≥24 mos) . | ||
|---|---|---|---|---|
| DARA (n = 125) . | Control (n = 115) . | DARA (n = 146) . | Control (n = 144) . | |
| Age, y | ||||
| Median (range) | 65 (30-89) | 65 (40-85) | 64 (34-84) | 64 (42-85) |
| ≥75 y, n (%) | 17 (13.6) | 17 (14.8) | 8 (5.5) | 16 (11.1) |
| ISS staging, n (%)∗ | ||||
| I | 62 (49.6) | 51 (44.3) | 73 (50.0) | 81 (56.3) |
| II | 45 (36.0) | 43 (37.4) | 45 (30.8) | 42 (29.2) |
| III | 18 (14.4) | 21 (18.3) | 28 (19.2) | 21 (14.6) |
| Cytogenetic risk, n (%)† | (n = 93) | (n = 93) | (n = 116) | (n = 96) |
| Standard | 72 (77.4) | 72 (77.4) | 94 (81.0) | 85 (88.5) |
| High | 21 (22.6) | 21 (22.6) | 22 (19.0) | 11 (11.5) |
Data shown of the pooled CASTOR and POLLUX data set.
The early-relapse subgroup included ITT patients with 1 prior line of therapy who progressed or relapsed <24 months after initiating their first line of therapy; the late-relapse subgroup included ITT patients with 1 prior line of therapy who progressed or relapsed ≥24 months after initiating their first line of therapy.
DARA, daratumumab; ITT, intent-to-treat.
ISS staging was based on the combination of serum β2-microglobulin and albumin.
Cytogenetic risk was assessed locally by fluorescence in situ hybridization or karyotype testing; high risk was defined as the presence of t(4;14), t(14;16), or del17p.